Yousif Capital Management LLC Sells 1,132 Shares of Xencor, Inc. (NASDAQ:XNCR)

Yousif Capital Management LLC reduced its stake in Xencor, Inc. (NASDAQ:XNCR) by 4.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 24,947 shares of the biopharmaceutical company’s stock after selling 1,132 shares during the quarter. Yousif Capital Management LLC’s holdings in Xencor were worth $530,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. CWM LLC raised its holdings in Xencor by 498.7% during the fourth quarter. CWM LLC now owns 1,377 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 1,147 shares during the period. Signaturefd LLC raised its holdings in Xencor by 367.7% during the fourth quarter. Signaturefd LLC now owns 1,464 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 1,151 shares during the period. abrdn plc bought a new stake in shares of Xencor in the fourth quarter worth about $3,726,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Xencor by 13.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,215 shares of the biopharmaceutical company’s stock worth $302,000 after purchasing an additional 1,640 shares during the last quarter. Finally, Louisiana State Employees Retirement System purchased a new position in Xencor in the fourth quarter worth about $648,000.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on XNCR shares. Piper Sandler reissued a “neutral” rating and set a $24.00 price target (down from $37.00) on shares of Xencor in a research note on Wednesday, February 28th. Mizuho cut their price target on shares of Xencor from $59.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, January 22nd. StockNews.com upgraded shares of Xencor from a “sell” rating to a “hold” rating in a report on Saturday, March 9th. Royal Bank of Canada restated an “outperform” rating and issued a $32.00 target price on shares of Xencor in a research note on Wednesday, February 28th. Finally, BTIG Research reduced their target price on shares of Xencor from $56.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, April 16th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Xencor presently has an average rating of “Moderate Buy” and an average price target of $36.00.

Xencor Price Performance

Shares of XNCR stock opened at $24.11 on Monday. The business’s fifty day simple moving average is $21.88 and its 200-day simple moving average is $20.50. The company has a quick ratio of 7.36, a current ratio of 7.36 and a debt-to-equity ratio of 0.02. Xencor, Inc. has a 12-month low of $16.49 and a 12-month high of $28.96.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.67). The business had revenue of $44.70 million for the quarter, compared to analyst estimates of $77.63 million. Xencor had a negative return on equity of 18.67% and a negative net margin of 74.90%. The business’s revenue for the quarter was up 106.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.20) earnings per share. As a group, analysts expect that Xencor, Inc. will post -3.25 earnings per share for the current year.

Insider Activity at Xencor

In related news, VP John R. Desjarlais sold 1,280 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $23.50, for a total value of $30,080.00. Following the transaction, the vice president now directly owns 186,433 shares of the company’s stock, valued at approximately $4,381,175.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, CEO Bassil I. Dahiyat sold 12,528 shares of the company’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $23.43, for a total value of $293,531.04. Following the transaction, the chief executive officer now directly owns 300,097 shares of the company’s stock, valued at approximately $7,031,272.71. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP John R. Desjarlais sold 1,280 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $23.50, for a total value of $30,080.00. Following the sale, the vice president now directly owns 186,433 shares in the company, valued at $4,381,175.50. The disclosure for this sale can be found here. Insiders have sold a total of 101,351 shares of company stock valued at $2,152,417 in the last ninety days. Company insiders own 5.23% of the company’s stock.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.